Találati lista | Tudóstér

001-es BibID:	BIBFORM092840
035-os BibID:	(cikkazonosító)347 (WoS)000633434800001 (Scopus)85101254453
Első szerző:	Bagoly Zsuzsa (orvos)
Cím:	Incorporation of [alfa]2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients / Bagoly Zsuzsa, Baráth Barbara, Orbán-Kálmándi Rita, Szegedi István, Bogáti Réka, Sarkady Ferenc, Csiba László, Katona Éva
Dátum:	2021
ISSN:	2218-273X
Megjegyzések:	Cross-linking of ?2-plasmin inhibitor (?2-PI) to fibrin by activated factor XIII (FXIIIa) is essential for the inhibition of fibrinolysis. Little is known about the factors modifying ?2-PI incorporation into the fibrin clot and whether the extent of incorporation has clinical consequences. Herein we calculated the extent of ?2-PI incorporation by measuring ?2-PI antigen levels from plasma and serum obtained after clotting the plasma by thrombin and Ca2+. The modifying effect of FXIII was studied by spiking of FXIII-A-deficient plasma with purified plasma FXIII. Fibrinogen, FXIII, ?2-PI incorporation, in vitro clot-lysis, soluble fibroblast activation protein and ?2-PI p.Arg6Trp polymorphism were measured from samples of 57 acute ischemic stroke patients obtained before thrombolysis and of 26 healthy controls. Increasing FXIII levels even at levels above the upper limit of normal increased ?2-PI incorporation into the fibrin clot. ?2-PI incorporation of controls and patients with good outcomes did not differ significantly (49.4 ? 4.6% vs. 47.4 ? 6.7%, p = 1.000), however it was significantly lower in patients suffering post-lysis intracranial hemorrhage (37.3 ? 14.0%, p = 0.004). In conclusion, increased FXIII levels resulted in elevated incorporation of ?2-PI into fibrin clots. In stroke patients undergoing intravenous thrombolysis treatment, ?2-PI incorporation shows an association with the outcome of therapy, particularly with thrombolysis-associated intracranial hemorrhage.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Biomolecules. - 11 : 3 (2021), p. 1-13. -
További szerzők:	Baráth Barbara (1991-) (orvosírnok) Orbán-Kálmándi Rita Angéla (1993-) (klinikai laboratóriumi kutató) Szegedi István (1992-) (orvos) Kissné Bogáti Réka (1988-) (tudományos segédmunkatárs) Sarkady Ferenc (1982-) (laboratóriumi analitikus) Csiba László (1952-) (neurológus, pszichiáter) Katona Éva (1961-) (klinikai biokémikus)
Pályázati támogatás:	GINOP-2.2.1-15-2017-00043 GINOP
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM091603
Első szerző:	Ząbczyk, Michał
Cím:	Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase / M. Zabczyk, J. Natorska, Z. Bagoly, F. Sarkady, B. Barath, E. Katona, A. H. Bryk, K. Zettl, J. R. Wisniewski, A. Undas
Dátum:	2020
ISSN:	0867-5910
Megjegyzések:	Fibrin cross-linking by coagulation factor (F)XIII leads to clot stabilization. Reduced plasma FXIII levels have been reported in acute pulmonary embolism (PE) patients. We investigated the impact of anticoagulant therapy on clot-bound amounts of FXIII and ?2-antiplasmin and their associations with fibrin clot properties in patients with PE. Clots generated from plasma of 18 acute symptomatic patients on admission and after a 3-month treatment with rivaroxaban were assessed off anticoagulation using mass spectrometry. Plasma FXIII and ?2-antiplasmin activity were determined at the 2 time points along with thrombin generation markers, plasma fibrin clot permeability (Ks), and clot lysis time (CLT). Following anticoagulant therapy, clot-bound FXIII increased from 2.97 (interquartile range, 1.98 ? 4.08) to 4.66 (3.5 ? 6.9) mg/g protein and ?2-antiplasmin from 9.4 (7.2 ? 10.6) to 11 (9.5 ? 14) mg/g protein (both p < 0.0001). The two parameters showed positive correlation at baseline only (r = 0.63, p = 0.0056). Similarly to clot-bound amounts, plasma FXIII (+25.8%) and ?2-antiplasmin activity (+12%) increased at 3 months. Plasma FXIII activity on admission, but not after 3 months since the index PE, was associated with amounts of clot-bound FXIII (r = 0.35, p = 0.043) and ?2-antiplasmin (r = 0.47, p = 0.048). At baseline, clot-bound FXIII correlated with plasma F1+2 prothrombin fragments levels (r = 0.51, p = 0.03), while clot-bound ?2-antiplasmin correlated with CLT (r = 0.43, p = 0.036). At 3 months associations of clot-bound FXIII and ?2-antiplasmin were abolished. This study assessed for the first time changes in the fibrin clot composition following acute PE, suggesting an increase of clot-bound and plasma FXIII and ?2-antiplasmin levels after 3 months.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Journal of Physiology and Pharmacology. - 71 : 4 (2020), p. 519-524. -
További szerzők:	Natorska, Joanna Bagoly Zsuzsa (1978-) (orvos) Sarkady Ferenc (1982-) (laboratóriumi analitikus) Baráth Barbara (1991-) (orvosírnok) Katona Éva (1961-) (klinikai biokémikus) Bryk, Agata Hanna Zettl, K. Wisniewski, J. R. Undas Anetta
Pályázati támogatás:	GINOP-2.3.2-15-2016-00043 GINOP
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: